ImmunityBio, a commercial-stage immunotherapy company, has secured $75 million in non-dilutive financing through an amendment to its Royalty Interest Purchase Agreement with Oberland Capital. This brings the total committed capital under the agreement to $375 million. The terms remain largely the same, with a slight adjustment to the royalty payback rate.
Amount: $75.0M
ImmunityBio Funding Round — ImmunityBio
